Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung

Pathology Research and Practice

Volumn 208, Issue 8, 2012, Pages 470-474

  Tsuta, Koji ^a,b   Wistuba, Ignacio I ^a   Moran, Cesar A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Lung; Neuroendocrine carcinoma; Somatostatin receptor

Indexed keywords

ISOPROTEIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; LUNG NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; TUMOR DIFFERENTIATION;

CARCINOID TUMOR; CARCINOMA, LARGE CELL; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; RECEPTORS, SOMATOSTATIN; SMALL CELL LUNG CARCINOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864095133     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.05.014     Document Type: Article

References (30)

1. Berenger N., Moretti J.L., Boaziz C., et al. Somatostatin receptor imaging in small cell lung cancer. Eur. J. Cancer 1996, 32A:1429-1431.
2. Brazeau P. Somatostatin: a peptide with unexpected physiologic activities. Am. J. Med. 1986, 81:8-13.
3. Bruns C., Lewis I., Briner U., et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 2002, 146:707-716.
4. Demetri G., Elias A., Gershenson D., et al. NCCN small-cell lung cancer practice guidelines. The national comprehensive cancer network. Oncology (Williston Park) 1996, 10:179-194.
5. Janson E.T., Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993, 32:225-229.
6. Janson E.T., Stridsberg M., Gobl A., et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. 1998, 58:2375-2378.
7. Kimura N., Pilichowska M., Date F., et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin. Cancer Res. 1999, 5:3483-3487.
8. Korner M., Eltschinger V., Waser B., et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am. J. Surg. Pathol. 2005, 29:1642-1651.
9. Krenning E.P., Valkema R., Kwekkeboom D.J., et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J. Nucl. Med. 2005, 46(Suppl. 1):76S-82S.
10. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 2005, 23:2754-2762.
11. Lamberts S.W., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1991, 12:450-482.
12. McMullan D.M., Wood D.E. Pulmonary carcinoid tumors. Semin. Thorac. Cardiovasc. Surg. 2003, 15:289-300.
13. Papotti M., Croce S., Bello M., et al. Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 2001, 439:787-797.
14. Papotti M., Croce S., Macri L., et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn. Mol. Pathol. 2000, 9:47-57.
15. Reichlin S., Somatostatin N. Engl. J. Med 1983, 309:1495-1501.
16. Reisinger I., Bohuslavitzki K.H., Brenner W., et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J. Nucl. Med. 1998, 39:224-227.
17. Reubi J.C., Kappeler A., Waser B., et al. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am. J. Pathol. 1998, 153:233-245.
18. Reubi J.C., Laissue J.A., Waser B., et al. Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: facts and artifacts. J. Clin. Endocrinol. Metab. 1999, 84:2942-2950.
19. Reubi J.C., Schaer J.C., Waser B., et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994, 54:3455-3459.
20. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:781-793.
21. Reubi J.C., Waser B., Foekens J.A., et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int. J. Cancer 1990, 46:416-420.
22. Righi L., Volante M., Tavaglione V., et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann. Oncol. 2010, 21:548-555.
23. Sandler A.B. Chemotherapy for small cell lung cancer. Semin. Oncol. 2003, 30:9-25.
24. Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann. Oncol. 1999, 10(Suppl 2):S17-S21.
25. Spiro S.G., Porter J.C. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am. J. Respir. Crit. Care Med. 2002, 166:1166-1196.
26. Travis W.D., Colby T., Corrin B., et al. Tumors of the lung. WHO Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart 2004, IARC Press, pp. 9-124. P. Kleihues, L.H. Sobin (Eds.).
27. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 1998, 22:934-944.
28. Volante M., Brizzi M.P., Faggiano A., et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod. Pathol. 2007, 20:1172-1182.
29. Wirth L.J., Carter M.R., Janne P.A., et al. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004, 44:213-220.
30. Zatelli M.C., Maffei P., Piccin D., et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J. Clin. Endocrinol. Metab. 2005, 90:2104-2109.